Tocilizumab (Actemra, intravenous) for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids
The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2014, [2014]
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) |
---|---|
Item Description: | Title from PDF caption. - "August 2014." |
Physical Description: | 1 PDF file (vii, 65 pages) illustrations |